Differential indications for atypical neuroleptics: Amisulprid, Clozapin, Olanzapin, Quetiapin und Risperidon. Results of a pilot study of prescription habits in psychiatric clinical usage in the BRD

• Published in: Nervenarzt Vol. 76; no. 3; pp. 278 - 284
• Main Authors: Günther, W, Laux, G, Trapp, W, Müller, N, Mitznegg, N, Schulze-Mönking, H, Steinberg, R, Wolfersdorf, M
• Format: Journal Article
• Language: German
• Published: Germany 01.03.2005
• Subjects: Antipsychotic Agents - administration & dosage; Data Collection; Drug Prescriptions - statistics & numerical data; Drug Utilization - statistics & numerical data; Drug Utilization Review - methods; Germany - epidemiology; Hospitals, Psychiatric - statistics & numerical data; Humans; Practice Patterns, Physicians' - statistics & numerical data; Psychiatry - statistics & numerical data; Schizophrenia - drug therapy; Schizophrenia - epidemiology; Germany
• ISSN: 0028-2804

With the introduction of atypical neuroleptics, the therapy of schizophrenia has been improved by a group of antipsychotic substances characterized by better tolerability concerning extrapyramidal side effects and higher efficiency against negative symptoms. However, these atypical antipsychotics are not a homogeneous class of drugs but rather represent a group of substances with very different neurobiologic, pharmacologic, and clinical features. This fact and the growing variety of available atypical neuroleptics illustrate the difficulty in choosing the "right" antipsychotic drug for each patient. The aim of this investigation was to evaluate preliminary empirical data for possible differential indication of atypical neuroleptics by a questionnaire-based survey of 192 physicians in ten psychiatric hospitals active in the biological psychiatry work group of the German Federal Directors' Conference.